It shouldn't be this way: Generic drug firms air frustration over EU risk management plans
This article was originally published in SRA
Executive Summary
Three years after the EU pharmacovigilance legislation came into force, generic drug companies are still struggling to comply with a mandatory provision under the law that requires them to prepare and submit risk management plans (RMPs) with their initial marketing authorization applications.